The faster a blood clot causing a stroke is removed, the less disability a patient may have, according to research presented at the American Stroke Association's International Stroke Conference 2016.
Previously, the SWIFT PRIME trial showed that patients with disabling ischemic (clot-caused) strokes were far less likely to die or be seriously impaired if their clots were physically removed with a clot retrieving device in addition to standard treatment with clot-busting drugs. In that trial, clot removal could be performed up to six hours after stroke onset.
In the current analysis of 83 patients who underwent clot removal, researchers examined whether patients did better if their clots were removed quicker. They found:
Overall, substantial blood flow was restored by clot removal in 88 percent of patients.
In those patients who had blood flow restored within 2.5 hours after stroke onset, 87 percent achieved functional independence (minimal or no disability).
Patients who had blood flow restored between 2.5 and 3.5 hours after stroke onset were 10 percent less likely to achieve functional independence than those who had earlier clot removal.
Every 60-minute delay after 3.5 hours resulted in a 15 percent lower likelihood of functional independence.
Researchers estimated that in a group of 100 stroke survivors, every six-minute delay in restoring blood flow would cost one survivor their functional independence, compared to those receiving early clot removal.
Any available multimedia related to these tips are on the right column of this link http://newsroom.
2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment
Clot-removal devices now recommended for some stroke patients
Join the AHA/ASA Support Network to talk with others going through similar journeys including depression after stroke.
Follow news from the American Stroke Association's International Stroke Conference 2016 via Twitter: @HeartNews #ISC16.
Statements and conclusions of study authors that are presented at American Stroke Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at http://www.